Education
About Us
Working with TipRanks
Follow Us
Cardiol Therapeutics (CRDL)
NASDAQ:CRDL
RESEARCH TOOLSreports
Total Valuation
Cardiol Therapeutics has a market cap or net worth of $78.03M. The enterprise value is $120.88M.
Market Cap$78.03M
Enterprise Value$120.88M
Share Statistics
Cardiol Therapeutics has 82.61M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding82.61M
Owned by Insiders5.34%
Owned by Instutions7.11%
Financial Efficiency
Cardiol Therapeutics’s return on equity (ROE) is -1.00 and return on invested capital (ROIC) is -104.86%.
Return on Equity (ROE)-99.58%
Return on Assets (ROA)-76.64%
Return on Invested Capital (ROIC)-104.86%
Return on Capital Employed (ROCE)-104.86%
Revenue Per Employee$0
Profits Per Employee-$1,642,545.727
Employee Count22
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cardiol Therapeutics is -2.52. Cardiol Therapeutics’s PEG ratio is -0.02.
PE Ratio-2.52
PS Ratio0.00
PB Ratio2.51
Price to Fair Value2.51
Price to FCF-2.81K
Price to Operating Cash Flow-2.82K
PEG Ratio-0.02
Income Statement
In the last 12 months, Cardiol Therapeutics had revenue of $0.00 and earned -$36.14M in profits. Earnings per share was -$0.54.
Revenue$0.00
Gross Profit-$190.29K
Operating Income-$24.18M
Pretax Income-$36.14M
Net Income-$36.14M
EBITDA-37.55M
Earnings Per Share (EPS)-0.54
Cash Flow
In the last 12 months, operating cash flow was -$25.93M and capital expenditures -$25.84K, giving a free cash flow of -$25.96M billion.
Operating Cash Flow-$25.93M
Free Cash Flow-$25.96M
Free Cash Flow per Share-$0.31
Dividends & Yields
Cardiol Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-0.04%
Earnings Yield-39.67%
Stock Price Statistics
Beta1.59
52-Week Price Change-46.37%
50-Day Moving Average1.13
200-Day Moving Average1.64
Relative Strength Index (RSI)33.14
Average Volume (3m)230.81K
Important Dates
Cardiol Therapeutics upcoming earnings date is May 20, 2025, TBA.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 20, 2025
Ex-Dividend Date―
Financial Position
Cardiol Therapeutics as a current ratio of 4.36, with Debt / Equity ratio of <0.01
Current Ratio4.36
Quick Ratio4.36
Debt to Market Cap<0.01
Net Debt to EBITDA1.25
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cardiol Therapeutics has paid -$4.00 in taxes.
Income Tax-$4.00
Effective Tax Rate>-0.01%
Enterprise Valuation
Cardiol Therapeutics EV to EBITDA ratio is -1.30, with an EV/FCF ratio of -1.43K.
EV to Sales0.00
EV to EBITDA-1.30
EV to Free Cash Flow-1.43K
EV to Operating Cash Flow-1.44K
Balance Sheet
Cardiol Therapeutics has $15.89M in cash and marketable securities with $165.98K in debt, giving a net cash position of -$15.72M billion.
Cash & Marketable Securities$15.89M
Total Debt$165.98K
Net Cash-$15.72M
Net Cash Per Share-$0.19
Tangible Book Value Per Share$0.43
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cardiol Therapeutics is $8.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$8.00
Price Target Upside733.33%
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast
EPS Growth Forecast